Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$12.58 USD
-0.91 (-6.75%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $12.55 -0.03 (-0.24%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ENTA 12.58 -0.91(-6.75%)
Will ENTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ENTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENTA
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
ENTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
Other News for ENTA
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)
Buy Rating Affirmed on Enanta Pharmaceuticals’ Promising Drug Pipeline and Strategic Expansion into Immunology
Oppenheimer Sticks to Their Hold Rating for Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals: Hold Rating Amid RSV Pipeline Progress and Financial Caution
Evercore ISI Sticks to Their Buy Rating for Enanta Pharmaceuticals (ENTA)